PR Newswire Clinical TrialsOriginal article
Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia
Phase 1positiveGENE202Positive
AI Analysis
Summary
Genespire and SR-TIGET reported positive preclinical data showing that ISLV-directed MMUT gene delivery achieved over 80% gene transfer efficiency in liver tissue of mouse models for methylmalonic acidemia. The lead candidate GENE202 is advancing toward clinical development.
Clinical Trial Data
Phase
Preclinical
Primary Endpoint
Met
Outcome Details
Preclinical study demonstrated durable therapeutic benefits with gene transfer efficiency exceeding 80% of liver tissue in mouse models
Importance:5/10
Sentiment:
0.70
gene therapyliver-directedmethylmalonic acidemiapreclinicalMMUT geneISLV delivery
Read the original article
Published by PR Newswire Clinical Trials on July 8, 2026 7:00 AM